THERANEXUS (EPA:ALTHX) DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Transparency directive : regulatory news
Lyon, April 15, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, publishes the total number of shares and voting rights forming its share capital ( In accordance with Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation) as of March 31, 2020.
| Date | Total of outstanding shares | Theoretical voting rights |
| March 31, 2020 | 3 622 413 | 4 920 863 |
|
| Contacts THERANEXUS Thierry Lambert Financial and Administrative Director investisseurs@theranexus.fr FP2COM Florence Portejoie Media Relations + 33 (0)6 07 76 82 83 fportejoie@fp2com.fr |
ACTUS finance & communication Caroline Lesage Investor Relations +33 (0)1 53 67 36 79 theranexus@actus.fr |
- SECURITY MASTER Key: yWdslMicYprJnptsaplubGiXmmyVxWWYaWfGx2NxYpucaGqVlGpnbZWYZm9jnmxs
- Check this key: https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
- Information on the total number of voting rights and shares making up the share capital
Full and original press release in PDF: https://www.actusnews.com/news/62976-theranexus_pr_ddv_31032020.pdf